Arda Therapeutics
Austin, US · Founded 2021 · Delaware corporation · 5 known investors
Arda develops therapeutics using single-cell computational biology to target and eliminate pathogenic cells in chronic diseases. The company combines drug development expertise with cellular biology to create new therapeutic approaches.
Founders & leadership
AF
Adam FreundFounder & Chief Executive Officer
RL
Remi-Martin LabergeFounder and Chief Technology Officer
VA
Vineeta AgarwalaDirector
Investors · 5
Reported raises · per SEC filings
Form D private placements▶$43.3MraisedOct 2024 · 17 investors · BiotechnologyRule 506(b)
▶$43.3MraisedOct 2024 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vineeta AgarwalaDirector
- Adam FreundExecutive Officer, Director
- Offering amount
- $43.4M
- Amount sold
- $43.3M
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$7.5MraisedJan 2022 · 10 investors · BiotechnologyRule 506(b)
▶$7.5MraisedJan 2022 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Adam FreundExecutive Officer, Director
- Offering amount
- $8.5M
- Amount sold
- $7.5M
- First sale
- Dec 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
- Sell or Invest in Arda Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · 2025
- Arda Therapeutics Raises $43M in Series A Financingfinsmes.com · 2024
- Arda Therapeutics Secures $43M Series A Financing to Advance Targeted Cell Depletion Therapies — Arda Therapeuticsardatx.com · 2024
- Exclusive: Lilly backs a16z-funded Arda Therapeutics’ $43M Series A to take ADCs into fibrosisendpoints.news · 2024
- Arda Therapeutics - $43M Early Stage Venture | Startup Introsstartupintros.com · 2024